Keith Davies

Keith Davies
T: +44 (0) 20 7246 0529
E: keith.davies@alantra.com

Keith is a Senior Consultant.

He works alongside our Partners and Directors to identify and get to know companies suitable for Alantra to work with. Keith has nearly 20 years’ experience of working in deal origination and research in M&A and private equity; he has a particular focus on the Business Services sector.

Before joining the team, Keith worked in services sector deal origination at mid-market private equity house Sovereign Capital, and prior to this in research and business development at Grant Thornton Corporate Finance. Previously he was head of research for the corporate finance advisory practice at Capita PLC.

Keith has experience of working with clients across a range of Business Services markets, including recruitment and HR, professional services and property & facilities services.

He has an MSc in Information Science from City University, and graduated with a BA in Philosophy from Middlesex University.

Outside of work Keith enjoys watching cricket and other sports, reading (particularly spy fiction), and music.

Alantra appoints experienced partner to head up its UK Real Estate & Hospitality team

Alantra has appointed Hoong Wey Woon as a Partner to head up its UK Real Estate & Hospitality team.  

Alantra advises Strong Roots on securing over €15.5m of investment

Alantra advises Strong Roots, one of the UK’s fastest-growing food companies, on securing over €15.5m of investment 

Alantra advises i2S on its sale to Gfi Informatique

Alantra advises Portuguese IT firm, i2S, on its sale to Gfi Informatique 

Alantra expands its technology sector team with two senior appointments

Alantra has expanded its Technology Media and Telecoms (TMT) sector team with two senior appointments. James Chapman-Andrews joins as Partner and Head of UK TMT and Simon Devonshire OBE, joins as Technology Industry Adviser.  

Alantra advises on sale of 3P Biopharmaceuticals to Keensight Capital

We advised Cinfa and the rest of the shareholders on the sale of 3P Biopharmaceuticals to Keensight Capital, a European growth private equity fund with deep expertise in healthcare.